Key result
In a comprehensive review of reported cases, cholesterol embolization syndrome was associated with a 92% incidence of atheroembolic renal disease and 63% mortality.
Cholesterol embolization syndrome is a highly morbid complication of cardiovascular interventions with a 63% mortality rate in reported cases.
Answers are grounded in this paper and cite their sources.
High mortality in reported cholesterol embolization cases warrants procedural vigilance; leaves open true incidence and prevention strategies from prospective studies.
Cholesterol embolization syndrome (CES) is a multi-systemic disease caused by embolization of atherosclerotic plaque contents from proximal large-caliber artery to distal small to medium arteries, occurring spontaneously or more commonly after vascular intervention. This report is a comprehensive review of the reported cases of CES found in our literature search. We discuss the risk factors, clinical manifestations, management, and prognosis of CES. The major predisposing factors for CES include older age, male sex, atherosclerotic cardiovascular risk factors, anticoagulation, and femoral access route. The composite incidence of atheroembolic renal disease was 92% and mortality 63%. Our review highlights the importance to recognize this disease entity for the cardiologist and nephrologist.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2017) conducted a review in Cholesterol embolization syndrome. Cholesterol embolization syndrome was evaluated on Incidence of atheroembolic renal disease and mortality. In a comprehensive review of reported cases, cholesterol embolization syndrome was associated with a 92% incidence of atheroembolic renal disease and 63% mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: